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Abstract
Background: The biguanides are a family of drugs with diverse clinical applications. Metformin, a widely used
anti-hyperglycemic biguanide, suppresses mitochondrial respiration by inhibiting respiratory complex I. Phenformin, a
related anti-hyperglycemic biguanide, also inhibits respiration, but proguanil, which is widely used for the prevention
of malaria, does not. The molecular structures of phenformin and proguanil are closely related and both inhibit isolated
complex I. Proguanil does not inhibit respiration in cells and mitochondria because it is unable to access complex I.
The molecular features that determine which biguanides accumulate in mitochondria, enabling them to inhibit
complex I in vivo, are not known.
Results: Here, a family of seven biguanides are used to reveal the molecular features that determine why phenformin
enters mitochondria and inhibits respiration whereas proguanil does not. All seven biguanides inhibit isolated complex
I, but only four of them inhibit respiration in cells and mitochondria. Direct conjugation of a phenyl group
and bis-substitution of the biguanide moiety prevent uptake into mitochondria, irrespective of the compound
hydrophobicity. This high selectivity suggests that biguanide uptake into mitochondria is protein mediated,
and is not by passive diffusion. Only those biguanides that enter mitochondria and inhibit complex I activate
AMP kinase, strengthening links between complex I and the downstream effects of biguanide treatments.
Conclusions: Biguanides inhibit mitochondrial complex I, but specific molecular features control the uptake
of substituted biguanides into mitochondria, so only some biguanides inhibit mitochondrial respiration in vivo.
Biguanides with restricted intracellular access may be used to determine physiologically relevant targets of
biguanide action, and for the rational design of substituted biguanides for diverse clinical applications.
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Background
Biguanides are commonly prescribed drugs for the treat-
ment of type II diabetes and to prevent malaria, and are
under investigation for their uses in cardiovascular dis-
ease and cancer [1–3]. Although their modes of action
in all of these applications are still debated, biguanides
with known anti-hyperglycemic properties (metformin,
phenformin, and buformin) have consistently been ob-
served to inhibit mitochondrial respiratory complex I
(NADH:ubiquinone oxidoreductase) at millimolar and
high micromolar concentrations [4–6]. Although these
inhibitory concentrations appear high, they are physiolo-
gically relevant because biguanides are positively charged
molecules and are thus concentrated inside mitochondria
by the mitochondrial membrane potential. Inhibition of
complex I leads to the activation of AMP-activated pro-
tein kinase (AMPK), which is thought to contribute to
biguanide anti-hyperglycemic activity [7, 8]. Furthermore,
biguanides have been found to inhibit the proliferation of
cancer cell lines [9, 10] and their mechanisms of action
(through mTORC1 in either an AMPK-dependent or
independent manner [3, 11]) are suggested to rely on the
inhibition of respiratory complex I; overexpression of the
yeast alternative NADH:ubiquinone oxidoreductase NDI1
was found to ablate the effect [12]. Conversely, although
the antimalarial biguanide cycloguanil and its pro-drug
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proguanil inhibit isolated complex I, they do not inhibit
cellular or mitochondrial respiration [4] and so, unlike the
anti-hyperglycemic biguanides, they are not associated
with lactic acidosis, a side effect of complex I inhibition.
Biguanides thus exhibit a wide range of physiological ef-
fects, and it is important to understand the factors that
determine their anti-hyperglycemic, anti-proliferative, and
anti-malarial effects, and the interplay between these
desirable effects and the undesirable side effect of lactic
acidosis.
For biguanides to inhibit mitochondrial respiration they
must cross both the plasma and mitochondrial inner
membrane to reach their binding site on complex I. Met-
formin transport across the plasma membrane is known
to involve organic cation transporters (OCT1–3) and mul-
tidrug and toxin extrusion proteins (MATE1–2) [13].
The human thiamine transporter (THTR-2) [14], the
serotonin transporter (SERT), and the plasma membrane
monoamine transporter (PMAT) have also been impli-
cated in metformin transport [15]. Biguanide uptake is
tissue specific due to varying levels of transporter ex-
pression [16, 17] and proximity to the hepatic portal
vein, owing to the first-pass effect [13]. In contrast to
the cellular-level understanding that has been reached
about metformin uptake by the intestines and liver, and
efflux by the liver and kidneys [13], very little is known
about how, once they have entered cells, biguanides
enter mitochondria.
There is no consensus yet on whether biguanides that
are more hydrophobic than metformin traverse biological
membranes by passive diffusion or require protein trans-
porters. Biguanides have high pKa values, so they are posi-
tively charged at neutral pH, and low partition coefficients,
suggesting they are only poorly lipophilic [18]. Even so,
many researchers have considered phenformin able to
cross biological membranes without requiring active trans-
port [6, 19, 20]. One study concluded that OCT1 mediates
the uptake of metformin but not phenformin by rat
hepatoma cells [8], because phenformin uptake was not
observed to be impaired by the OCT1 inhibitor quini-
dine. Conversely, the organic cation/carnitine transporter
1 (OCTN1) in the mitochondrial inner membrane [21]
was found to contribute to phenformin uptake [22]. Irre-
spective of the mode of transport, the very different levels
of uptake of different biguanides with comparable lipophi-
licity (such as phenformin and proguanil) [4] argues for
their selective transport across the mitochondrial inner
membrane.
Here, we aim to determine why some biguanides are
able to enter mitochondria and inhibit respiration whereas
others (of comparable or greater hydrophobicity) are not,
and to determine whether uptake into the mitochondrial




Phenformin, phenyl biguanide (PubChem CID: 5932)
(Sigma-Aldrich Ltd.), isopropyl biguanide (PubChem CID:
9570185), chlorophenformin (PubChem CID: 67587204)
(AKOS GmbH), and benzyl biguanide (PubChem CID:
9570091) (Angene International Ltd.) were added from
aqueous stock solutions, and proguanil (Sigma-Aldrich
Ltd.) and bis-isopropyl biguanide (PubChem CID:
23437065) (European Directorate for the Quality of
Medicines and Healthcare) from stock solutions in
DMSO.
Preparation of proteins, membranes, and mitochondria
Complex I and mitochondrial membranes were prepared
from Bos taurus (bovine) heart [23]. Intact mitochondria
were isolated from rat liver [24] and mouse heart and
liver [25]. Membranes were prepared from mouse heart
mitochondria by 5 s bursts of sonication at 4 °C and
collected by centrifugation (75,000 × g, 1 h).
Kinetic measurements on complex I and mitochondrial
membranes
Assays were performed at 32 °C in a SpectraMax 96-well
plate reader. NADH:decylubiquinone oxidoreduction by
complex I at 0.5 μg mL−1 was measured in 20 mM Tris-
HCl (pH 7.2), 0.15 % soy bean asolectin (Avanti Polar
Lipids), and 0.15 % 3-((3-cholamidopropyl)dimethylam-
monium)-1-propanesulfonate (CHAPS, Merck Chemicals
Ltd), with 200 μM decylubiquinone and 200 μM NADH,
and monitored using ε340–380(NADH) = 4.81 mM
−1 cm−1
[23]. Catalysis was initiated by addition of NADH and
maximal rates determined by linear regression. NADH:O2
oxidoreduction by membranes was measured similarly but
using 5 μg mL−1 membranes in 10 mM Tris-HCl (pH 7.4)
and 250 mM sucrose using 200 μM NADH and supple-
mented with 0.15 mM horse heart cytochrome c (Sigma-
Aldrich Ltd.). Succinate:O2 oxidoreduction was measured
using 40 μg mL−1 membranes in 5 mM succinate in
10 mM Tris-HCl (pH 7.4) as described previously [26].
Control experiments included NaCl (to match the ionic
strength) or DMSO, as appropriate.
Cell lines
143B (CRL-8303 from ATCC), HepG2 (85011430 from
The Health Protection Agency), and MDBK (CCL-22
from ATCC) cells were grown on Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10 % fetal
bovine serum (FBS, Thermo Fisher Scientific) at 37 °C
in 5 % CO2. All cells were confirmed as negative for
mycoplasma.
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Oxygen consumption rate measurements on intact and
permeabilized cells
Oxygen consumption rates (OCRs) were measured using
a Seahorse XF96 extracellular flux analyzer at 37 °C. For
intact cell measurements, 1.4 × 104 143B, HepG2, or
MDBK cells were plated (per well) in DMEM containing
10 % FBS into Seahorse Bioscience Inc. XF96 plates and
incubated for ~12 h at 37 °C in 5 % CO2. Then, the
medium was exchanged for assay buffer containing
DMEM, 4.5 g L−1 glucose, 1 mM pyruvate, 32 mM NaCl,
2 mM GlutaMAX, 15 mg L−1 phenol red, and 20 mM
HEPES (pH 7.4 at 37 °C) and the cells placed in a
CO2-free incubator at 37 °C for 30 min. Basal oxygen
consumption rates were established before the addition
of biguanides at one-tenth of their IC50 (IC50/10), and
followed for ~ 6 h before the addition of rotenone
(2 μM).
For permeabilized cell experiments, cells were seeded
into XF96 plates at 0.9–1.1 × 104 per well and incubated
for 48 h at 37 °C in 5 % CO2. Then, the growth medium
was exchanged for assay buffer containing 3 nM plasma
membrane permeabilizer ‘PMP’ (Seahorse Biosciences
Inc.), 10 mM glutamate, 10 mM malate, 220 mM manni-
tol, 70 mM sucrose, 10 mM KH2PO4, 5 mM MgCl2,
1 mM EGTA, 0.2 % fatty acid-free bovine serum albu-
min (BSA), and 2 mM HEPES (pH 7.4 at 37 °C). The
permeabilized cells were incubated with 10 mM glutam-
ate and 10 mM malate for 25 min prior to the addition
of biguanides at IC50/5 or IC50. The biguanides were
allowed to accumulate for 30 min, then respiration was
uncoupled by the addition of 4 mM ADP. Rotenone was
added (2 μM) at the end of the experiment.
Rotenone-sensitive OCRs were calculated by subtract-
ing the rotenone-insensitive rates (determined at the end
of the experiment). OCRs were normalized by dividing
by the OCR recorded immediately prior to the addition
of biguanide. For rate of uptake calculations, the OCRs
at time points after biguanide addition were divided by
the OCRs at the same time points in control experi-
ments. Data from wells with failed port injections were
excluded from the analyses. The respiratory control ratio
(RCR) values (state III versus state IV respiration) were
~11 and ~6 for permeabilized MDBK and 143B cells,
respectively.
OCR measurements on isolated mitochondria
Isolated mitochondria were monitored using a Seahorse
XF96 extracellular flux analyzer at 32 °C. Mouse heart
mitochondria, and mouse and rat liver mitochondria
were plated into XF96 plates at 4 and 16–20 μg per well,
respectively, in 220 mM mannitol, 70 mM sucrose,
10 mM KH2PO4, 5 mM MgCl2, 1 mM EGTA, 0.2 % fatty
acid-free BSA, and 2 mM HEPES (pH 7.4 at 37 °C) with
10 mM glutamate and 10 mM malate and adhered by
centrifugation (2000 × g, 20 min, 4 °C). The medium was
supplemented with a further 5 mM glutamate and 5 mM
malate and the mitochondria incubated for 15 min. Then
two baseline readings were taken before the biguanides
were added at IC50/5. Biguanides were allowed to accumu-
late for 15–20 min before respiration was uncoupled by
the addition of 4 mM ADP. Rotenone (2 μM) was added
at the end of the experiment. Data from wells with failed
port injections were excluded from the analyses. The RCR
values (state III versus state IV respiration) were 3.4,
4.8, and 4.6 for mouse heart, rat liver, and mouse liver,
respectively.
Membrane potential measurements
143B cells were seeded at 5 × 105 cells per 10 cm2 well
in DMEM containing 10 % FBS. On the following day
they were treated with 34 μM phenformin (IC50/10) for
6.5 h then washed once with phosphate-buffered saline
(PBS) and detached using TrypLE (Thermo Fisher Scien-
tific). The detached cells from each well were incubated in
PBS containing 25 pg/mL tetramethylrhodamine, methyl
ester (TMRM) and 20 μg/mL Hoescht stain for 20 min at
37 °C then washed twice and re-suspended in 200 μL PBS.
TMRM fluorescence was detected using a NucleoCounter®
NC 3000 cytometer with excitation at 530 nm and emis-
sion at 575 nm, with the Hoescht stain used to check for
consistent cell density between samples.
Analysis of AMPK activation
MDBK cells were seeded at 1 × 106 cells per 6 cm dish
in DMEM containing 10 % FBS. Cells were then serum
starved in DMEM containing 25 mM HEPES for 6 h
before biguanides were added at IC50/10. After 18 h
cells were harvested by a rapid lysis procedure [27]:
cells were rinsed with PBS, then lysed using ice-cold
buffer containing 50 mM HEPES, 1 mM EDTA, 10 %
glycerol, 50 mM NaF, 5 mM sodium pyrophosphate,
1 % Triton-X100, 1 mM dithiothreitol (DTT), and a
protease inhibitor cocktail (Roche). The cell lysate was
centrifuged at 14,000 × g for 20 min at 4 °C and the
protein concentration of the supernatant determined by
bicinchoninic acid assay. The lysate was analyzed using
Novex 3–12 % bis-Tris gels run in 3-(N-morpholino)-
propanesulfonic acid (MOPS) buffer (20 μg of protein
per lane) followed by transfer to low fluorescence
polyvinylidene fluoride membranes by wet transfer.
Primary rabbit antibodies for AMPK-β (57C12), AMPK-α
(phospho-Thr172) (40H9), and acetyl-coA carboxylase
(phospho-Ser79) (Cell Signaling Technology) were incu-
bated overnight with the membrane (1:1000 dilution) in
Odyssey blocking buffer at 4 °C. A fluorescent secondary
antibody was used (IRDYE800CW from LI-COR Biosci-
ences, 1:20,000 dilution) with a LI-COR Odyssey imaging
system.
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Partition coefficients
Octanol/PBS partition coefficients were measured by the
shake-flask method [28] at 32 °C, pH 7.4.
Statistical methods
Experimental values are reported as mean averages ±
standard deviation (SD) of technical replicates for large
sample sizes and mean averages ± standard error of the
mean (SEM) of technical replicates for small sample
sizes. Data were analyzed by the unpaired two-tailed
Student’s t test. IC50 values were determined using the
standard dose-effect relationship (activity (%) = 100 ×
IC50 / (IC50 + [inhibitor]
m) [29] with the Hill Slope (m)
set to unity for purified complex I) and are reported
with 95 % confidence intervals.
Results and discussion
Experimental strategy
To delineate the effects that determine whether biguanides
are able to cross the mitochondrial inner membrane we
focused on phenformin and proguanil. They have simi-
lar partition coefficients [4], so their passive transport
across the membrane should be comparable; however,
they are taken up into the mitochondrial matrix with
very different rates and to very different extents. Both
compounds are effective inhibitors of isolated complex
I, but only phenformin inhibits complex I in mitochon-
dria [4]. The molecular structure of proguanil differs
from that of phenformin in four ways (Fig. 1a): its
phenyl ring is chlorinated; it has no linker between
the phenyl ring and the biguanide moiety (phenfor-
min has a two-carbon linker); its biguanide moiety is
bis-substituted (phenformin is mono-substituted); and
it contains an isopropyl substitution. Five biguanides were
designed to test each difference (Fig. 1a): 2-[2-(4-chloro-
phenyl)ethyl]-1-(diaminomethylidene)guanidine) (chloro-
phenformin, compound 1) tests the effect of adding a
chlorine to the phenyl ring; phenyl biguanide (compound
2) and 2-benzyl-1-(diaminomethylidene)guanidine (benzyl
biguanide, compound 3) test the effect of the linker
between the phenyl ring and the biguanide moiety; 1-
(diaminomethylidene)-2-(propan-2-yl)guanidine (isopropyl
biguanide, compound 4) tests the effect of the isopropyl
derivative; and N-(propan-2-yl)-1-3-(propan-2-yl)carbami-
midamidomethanimidamide (bis-isopropyl biguanide, com-
pound 5) tests the effect of bis-substituting the biguanide
functionality.
Biguanide effects on isolated complex I and
mitochondrial membranes
All seven compounds described were effective inhibitors
of NADH:decylubiquinone oxidoreduction by isolated bo-
vine complex I, as well as of NADH:O2 oxidoreduction
(catalysis by complexes I-III-IV) by bovine and mouse
heart mitochondrial membranes (Fig. 1b and Additional
file 1), and the IC50 values for each biological system were
comparable. Subsequent assays on human cell lines were
based on the IC50 values from bovine heart membranes,
and assays on mouse mitochondria on the IC50 values
from mouse heart membranes. Assays of succinate:O2
oxidoreduction (catalysis by complexes II-III-IV) by bo-
vine membranes, using concentrations equivalent to the
IC50 values for NADH:O2 oxidoreduction, confirmed the
inhibition is specific to complex I (Fig. 1c and Additional
file 1). Finally, partition coefficients that describe com-
pound hydrophobicity were measured for each compound
at pH 7.4 (at which pH all the biguanides are positively
charged). A correlation between inhibitory efficacy and
hydrophobicity was observed (Fig. 1d and Additional
file 1) that extends and confirms that observed previ-
ously with a smaller number of compounds [4]. Improved
transmembrane diffusion as a result of their greater hydro-
phobicity has previously been suggested as a reason why
phenformin and buformin are more potent inhibitors of
cellular respiration than metformin [30], but our data
explain that this correlation is observed because the
more hydrophobic compounds are better complex I
inhibitors.
Biguanide effects on oxygen consumption by cells and
mitochondria
All the compounds studied inhibit isolated complex I, so
inhibition of oxygen consumption by the respiratory
chain can be exploited as a marker for their presence
and concentration in the mitochondrial matrix, the com-
partment containing the complex I biguanide-binding
site. Notably, this approach to evaluating the matrix bi-
guanide concentration avoids the need for radioactive
biguanides, estimation of matrix volume, or lengthy isola-
tion protocols. To account for the wide range of complex
I IC50 values observed across the compound series, con-
centrations relative to the individual IC50 values were
used. Biguanides were added to cells at one-tenth of their
IC50 concentrations, and the rotenone-sensitive OCRs
monitored for 6 h. At IC50/10 a biguanide that does not
enter mitochondria does not inhibit respiration, whereas a
biguanide that can enter the matrix accumulates based on
its intrinsic positive charge and the membrane potential
and so progressively inhibits respiration. Experiments with
human osteosarcoma 143B (Fig. 2a) and hepatocarcinoma
HepG2 cells (Fig. 2b) revealed that compounds 1, 3, and 4
inhibit respiration (like phenformin they enter mitochon-
dria), but compounds 2 and 5 do not (like proguanil they
do not enter mitochondria). The same pattern was ob-
served in experiments using a kidney cell line from Bos
taurus (MDBK) (Fig. 2c) although the drugs were much
slower to take effect. Thus, after 6 h of exposure, 143B
and HepG2 cells were inhibited to a similar level, and
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MDBK cells were less inhibited (Fig. 2d and Additional
file 1).
The data on intact cells suggest the presence of a se-
lectivity barrier at either the plasma membrane and/or
the mitochondrial inner membrane. Therefore, the com-
pounds were tested at concentrations of IC50/5 on MDBK
cells in which the plasma membrane had been perme-
abilized (Fig. 3a, b), and on isolated mitochondria from
mouse heart, mouse liver, and rat liver (Fig. 3c, d). The
same pattern of inhibition was observed in all cases,
showing that transport across the mitochondrial inner
membrane is selective. Even much higher (IC50) con-
centrations of compounds 2, 5, and proguanil elicited
only limited inhibition of the OCR in permeabilized
143B cells (Fig. 3b and Additional file 1). Furthermore,




Fig. 1 Characterization of the effects of seven biguanides on mitochondrial respiration. a Differences in molecular structure between phenformin
and proguanil and the five test compounds (all compounds shown in the neutral form). b Biguanide IC50 values for inhibition of NADH:decylubiquinone
oxidoreduction by isolated bovine heart complex I (white), and NADH:O2 oxidoreduction by bovine heart (light gray) and mouse heart
(dark gray) mitochondrial membranes. The data from three or four technical replicates were fit using Prism, and presented as best-fit IC50
values with 95 % confidence intervals. c Inhibition of succinate:O2 oxidoreduction in bovine mitochondrial membranes by biguanides at
concentrations equivalent to the IC50 values for NADH:O2 oxidoreduction. Data are mean values ± standard error of the mean (SEM) (n = 3); *p≤ 0.05.
d Correlation between the IC50 values for isolated bovine complex I and the octanol:PBS partition coefficients (log10P values) of the
biguanides. Compounds that inhibit cellular and mitochondrial respiration strongly (see main text) are shown with open symbols and
gray text, and those that do not with closed symbols and black text. The dagger (†) indicates values reported previously [4]. Data for
log10P are mean values ± SEM (n = 3). Individual data points for panels b, c, and d are provided in Additional file 1. phenf. phenformin,
prog. proguanil
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experiment using mouse heart mitochondria in which
ADP was added at the same time as phenformin [oxygen
consumption was 85 ± 10 % of the control value (n = 8
with phenformin and n = 6 for control, see Additional
file 2), compared to 30 % in the absence of ADP (see
Fig. 3d and Additional file 1)], confirming that biguan-
ide accumulation into mitochondria depends on the
membrane potential [12]. Finally, the inhibition of the
OCR observed in intact mitochondria respiring on glu-
tamate and malate confirms that it is due to inhibition
of complex I, not mitochondrial glycerol-3-phosphate
dehydrogenase (mGPD) [31]. mGPD has also been pro-
posed as a target for biguanides [31] and could contrib-
ute to the inhibition of the OCR in intact cells because
it couples oxidation of the NADH produced by glycoly-
sis in the cytoplasm to reduction of O2 by complex IV.
However, the malate/aspartate shuttle also performs
this function, and mGPD does not contribute to oxygen
consumption by isolated mitochondria because they
lack any connection with cytoplasmic processes.
The molecular determinants of biguanide uptake
Our data clearly delineate compounds 1, 3, and 4 that
can cross both the plasma and mitochondrial inner
membrane (like phenformin) from compounds 2 and 5
that cannot (like proguanil). Thus, conjugation of a phenyl
ring directly to the biguanide moiety (compound 2) and
bis-substitution of the biguanide (compound 5) prevent
biguanides from accessing the matrix and inhibiting res-
piration; both features are present in proguanil. A chloro-
group on the ring (compound 1) and the iso-propyl group
itself (compound 4), which are also present in proguanil,
do not prevent inhibition. The inhibition observed previ-
ously from alkyl biguanides, including the anti-diabetic
compounds metformin and buformin [4, 32], is fully con-
sistent with our results.
Rate and extent of biguanide uptake
Biguanide uptake into mitochondria depends on the
mitochondrial membrane potential. However, once in-
side mitochondria, biguanides inhibit complex I and
C D
Fig. 2 Biguanide inhibition of rotenone-sensitive respiration in intact cells. Panels a–c show the progression of rotenone-sensitive oxygen consumption
rates (OCRs) in 143B (a), HepG2 (b), and MDBK (c) cells following addition of biguanides. The traces are the means ± standard deviation (SD) of multiple
traces. For 143B, n = 9 for control and proguanil; n = 11 for phenformin and compounds 2 and 5; and n =12 for compounds 1, 3, and 4. For HEP G2,
n = 9 for control and proguanil; n = 11 for phenformin and compounds 2 and 3; and n= 12 for compounds 1, 4, and 5. For MDBK, n = 8 for control;
n = 7 for compounds 1 and 5; and n = 6 for phenformin, proguanil, and compounds 2, 3, and 4. Biguanide concentrations were set to IC50/10: 34 μM
phenformin; 40 μM compound 1, 42 μM compound 2; 97 μM compound 3; 2.88 mM compound 4; 32 μM compound 5; and 2 μM proguanil.
d Rotenone-sensitive OCRs in 143B (black), HepG2 (gray), and MDBK (white) cells after 6 h of biguanide incubation (% of the control, error bars
show propagated SD). Individual data points for panel d are provided in Additional file 1. con. control, phenf. phenformin, prog. proguanil
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thus may decrease the membrane potential, resulting in a
negative feedback loop that will eventually balance the
two effects. To evaluate the effects of phenformin on
membrane potential, 143B cells were treated with phen-
formin at IC50/10 to match the experiment in Fig. 2a, and
the membrane potential was evaluated using the fluores-
cence of TMRM. After 6.5 h, the TMRM fluorescence was
22.4 ± 2.9 % (n = 3) of the control value, compared to
13.43 ± 1.7 % (n = 3) in cells treated with 1 μM of the
uncoupler carbonyl cyanide-4-(trifluoromethoxy)phenyl-
hydrazone (FCCP) (Additional file 3). Although the TMRM
fluorescence is not a quantitative measure, it is clear that
phenformin treatment induces a decrease in the membrane
potential. We previously found that, in addition to their
effects on complex I, biguanides also directly inhibit ATP
hydrolysis by F1Fo ATP synthase, hindering the use of ATP
hydrolysis to support the membrane potential [4] when the
respiratory chain is inhibited.
In order to evaluate how the matrix biguanide concen-
tration varies in intact cells, inhibition of the OCR was
exploited as a real-time marker by comparison with the
IC50 data from complex I in membranes (Fig. 4a). Note
that we are unable to include the effects of the decreased
membrane potential (which acts to increase the OCR, op-
posing the inhibition) in our calculation, so the calculated
values are underestimates of the true matrix concentra-
tion. Figure 4a shows how the estimated matrix phenfor-
min concentration evolves over time, with maximal rates
C D
Fig. 3 Biguanide inhibition of rotenone-sensitive respiration in permeabilized cells and isolated mitochondria. a MDBK permeabilized cells treated
with biguanides at IC50/5 for 30 min before ADP was added to stimulate the rates. Data show means ± standard deviation (SD) (n = 16 for
control, n = 5 for proguanil and compound 2, n = 6 for compound 3, n = 7 for compound 1, and n = 8 for phenformin and compounds 4
and 5). b ADP-stimulated rotenone-sensitive oxygen consumption rates (OCRs) in permeabilized cells (% of the control, error bars show
SD values). For permeabilized 143B cells: n = 10 for control, compounds 1, 2, and 4; n = 11 for phenformin and compound 3; n = 8 for compound 5;
and n = 9 for proguanil. Black, data taken from Fig. 3a; gray, equivalent data from permeabilized 143B cells but using biguanide concentrations equal
to IC50. c Mouse heart mitochondria respiring on glutamate and malate were exposed to biguanides for 15 min before ADP was added to stimulate
the rates. Biguanides concentrations were set to IC50/5 (using the IC50 values for mouse heart mitochondrial membranes): 0.16 mM phenformin,
0.094 mM compound 1, 0.17 mM compound 2, 0.63 mM compound 3, 6 mM compound 4, 0.058 mM compound 5, and 0.002 mM proguanil. Data
show means ± standard error of the mean (SEM) (n = 8 for all compounds and n = 12 for control). d Inhibition of the ADP-stimulated rotenone-
sensitive OCR in mitochondria (% of the control; mean ± SEM. For mouse liver mitochondria: n = 5 for control; n = 3 for compounds 1, 2, and 4; and
n = 4 for all other compounds. For rat liver: n = 5 for control, n = 3 for proguanil and compound 5, and n = 4 for all other compounds. Black, data taken
from Fig. 3c; gray, rat liver mitochondria; white, mouse liver mitochondria. For panels b and d, ****p≤ 0.0001, ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05. Individual
data points for panels b and d are provided in Additional file 1. con. control, phenf. phenformin, prog. proguanil, rot. rotenone
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of accumulation of 136, 85, and 3.2 μM min−1 for HepG2,
143B, and MDBK cells, respectively. Figure 4b compares
rates of uptake of each compound into each cell line, con-
firming that the weak inhibition in MDBK cells (Fig. 2c) is
due to slow biguanide uptake. For the four biguanides
(phenformin and compounds 1, 3, and 4) that are taken
up into mitochondria, the estimated rates range from
>1.5 mM min−1 for compound 4 into 143B and HepG2
cells (3 mM in the extracellular medium) to 1 μM min−1
for compound 1 into MDBK cells (37 μM in the extracel-
lular medium); because the biguanides are present in the
medium at different absolute concentrations, the rates
are not directly comparable. Figure 4c compares the
extent of accumulation after 30 min of biguanide ex-
posure for intact and permeabilized MDBK cells, calcu-
lated in the same way (see also Additional file 1). On
this timescale the intramitochondrial concentrations in
intact cells hardly reach the concentration in the extra-
cellular medium, whereas in permeabilized cells the
compounds accumulate significantly into mitochondria,
with compound 3 accumulating more than 200-fold.
Therefore, the slow uptake of the mitochondria-permeant
biguanides observed in MDBK cells is due to slow trans-
port across the plasma membrane.
Is biguanide transport protein mediated or determined
by membrane solubility?
The transport of metformin across the plasma membrane
by OCTs is widely accepted, but more hydrophobic bigua-
nides like phenformin have been widely considered to cross
biological membranes by passive transport [6, 19, 20]. The
most hydrophobic biguanide tested here, proguanil, is
known to cross the plasma membrane into liver cells be-
cause it is converted to cycloguanil by P450s [33], but it
does not reach the mitochondrial matrix to inhibit com-
plex I. Here, we have shown that selective transport across
the inner membrane both prevents proguanil (and com-
pounds 2 and 5) from accumulating in mitochondria, and
B C
Fig. 4 Determination of matrix phenformin concentrations in cells. a Oxygen consumption rate (OCR) as a percentage of the control for HepG2
(black), 143B (gray), and MDBK (white) cells, taken from Fig. 2 (left, 34 μM phenformin = IC50/10), is combined with the IC50 curve for phenformin
inhibition of complex I in bovine mitochondrial membranes (middle), providing estimates for the matrix phenformin concentration (right).
b Maximal rates of biguanide uptake into the matrix were calculated by linear regression from the data in Fig. 2a–c. Dark gray, 143B; light gray,
HepG2; white, MDBK. c Biguanide concentration in the matrix relative to in the extracellular medium after 30 min in intact (white) MDBK and
permeabilized (red) MDBK cells. For intact cells: n = 8 for control; n = 7 for compounds 1 and 5; and n = 6 for phenformin, proguanil, and
compounds 2, 3, and 4. For permeabilized cells: n = 16 for control; n = 8 for phenformin and compounds 4 and 5; n = 7 for compound 1; n = 6
for compound 3; and n = 5 for proguanil and compound 2. The values for compounds 3 and 4 are underestimates as inhibition exceeded
90 %. Data show means ± standard error of the mean. Individual data points for panel c are provided in Additional file 1. phenf. phenformin,
prog. proguanil
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facilitates the rapid uptake of phenformin (and com-
pounds 1, 3, and 4). This selectivity strongly suggests that
transport is protein mediated. By extension, the different
uptake rates between cell lines can be ascribed to different
expression levels of transporter proteins, particularly in
the plasma membrane. Here, we observed the slowest
uptake in bovine kidney cells, and it has been observed
that biguanide uptake into human HEK293 kidney cells is
very slow unless OCTs are overexpressed [34]. Hepatic
cells (like HepG2) are known to have high OCT1 expres-
sion levels for biguanide uptake and, conversely, kidney
cells have high MATE1 expression levels for biguanide
efflux [16]. Although the simplest explanation for our data
is selective biguanide uptake into mitochondria, the influ-
ence of highly active and selective efflux processes cannot
be excluded.
Activation of AMPK by biguanides
The anti-hyperglycemic and anti-proliferative activities
of biguanides have been linked to the activation of AMPK
[7, 8] and so the ability of each biguanide to activate
AMPK was investigated in MDBK cells. Figure 5 shows
the levels of activation of AMPK (and its downstream
effector acetyl-coA carboxylase, ACC) achieved following
18-h treatments with IC50/10 biguanide concentrations.
The antibodies to AMPK-α and ACC detect the phos-
phorylated forms (with the detection of AMPK-β as a con-
trol) and AMPK activation was observed only for those
biguanides that inhibit mitochondrial respiration. Indeed,
the slightly lower activation observed for phenformin and
compound 1 is consistent with their less efficient inhib-
ition in this cell line (Fig. 2c).
Our data indicate that access to the mitochondrial
matrix is necessary for biguanide-mediated AMPK activa-
tion, so it is unlikely that an extra-mitochondrial enzyme
is the primary target responsible for AMPK-related down-
stream effects of biguanide treatments. AMP deaminase
in the cytoplasm and mGPD in the intermembrane space
have both been proposed as primary extra-mitochondrial
targets of metformin [31, 35]; our results suggest that the
inhibition of neither of them is linked to the activation of
AMPK. Consistent with this picture, acute metformin
treatments were observed to inhibit mGPD and cause
plasma glucose to drop, but not to activate AMPK [31],
whereas long-term metformin treatments did activate
AMPK. Whether the anti-hyperglycemic effects of metfor-
min (and phenformin) are mediated by AMPK activation
[7, 36, 37] or by alternative signaling pathways [2, 38] (or
both) is thus still debated. The anti-proliferative effects of
biguanides have been more closely linked to inhibition of
complex I, as they were ablated by overexpression of the
yeast alternative NADH:ubiquinone oxidoreductase NDI1
[12]; they may be mediated by mTORC1 in either an
AMPK-dependent or independent manner [3, 11].
Conclusions
All the biguanides tested inhibit mitochondrial complex
I, but only some biguanides inhibit mitochondrial respir-
ation in vivo. Here, we have identified the specific mo-
lecular features that control the uptake of substituted
biguanides into mitochondria and allow them to target
complex I: direct conjugation of a phenyl group and
bis-substitution of the biguanide moiety prevent up-
take into mitochondria, irrespective of the compound
hydrophobicity. The high selectivity suggests that bi-
guanide uptake into mitochondria is protein mediated,
and is not by passive diffusion. Only biguanides that enter
mitochondria and inhibit complex I activate AMP kinase.
Our results can be applied in the design of new complex
I-targeted biguanides with improved anti-proliferative ac-
tivity [39], and to assist in deconvoluting the targets and
mechanisms of action of anti-hyperglycemic biguanides
like metformin.
A B
Fig. 5 AMP-activated protein kinase (AMPK) activation by biguanides in MDBK cells. a Western blot against phospho-acetyl-coA carboxylase (p-ACC),
phospho-AMPK-α (AMPK p-α), and AMPK-β. Cells were incubated for 18 h with biguanide concentrations equivalent to IC50/10. b Quantification of
western blot band intensities; the signals from p-ACC and AMPK p-α were normalized to the signals for AMPK-β, and then further normalized to the
control values. Data show the mean of independent experiments ± standard error of the mean (n = 3). Individual data points for panel B are provided
in Additional file 1. phenf. phenformin, prog. proguanil
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Additional files
Additional file 1: Supporting information and individual data points for
figures 1b, 1c, 1d, 2d, 3b, 3d, 4c, and 5b. (XLSX 152 kb)
Additional file 2: Individual data points for mouse heart mitochondria
simultaneously uncoupled with ADP and inhibited with phenformin.
(XLSX 56 kb)
Additional file 3: Data for TMRM measurements on 143B cells.
(XLSX 47 kb)
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